Chikungunya Fever - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H1 2017, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 18 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chikungunya Fever - Overview
Chikungunya Fever - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chikungunya Fever - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chikungunya Fever - Companies Involved in Therapeutics Development
Abivax SA
Arbovax Inc
Arno Therapeutics Inc
Bharat Biotech International Ltd
Ennaid Therapeutics LLC
Etubics Corp
Griffith University
Hawaii Biotech Inc
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Integrated BioTherapeutics Inc
Merck & Co Inc
Mymetics Corp
Nanotherapeutics Inc
PaxVax Inc
Profectus BioSciences Inc
Shionogi & Co Ltd
Takeda Pharmaceutical Company Ltd
Themis Bioscience GmbH
Theravectys SA
Valneva SE
Vaxart Inc
Chikungunya Fever - Drug Profiles
(chikungunya + Zika) (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-1089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-1091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBV-87 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya (viral like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya (viral like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chikungunya vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSRx-431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMCKV-063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Chikungunya and Ross River Virus Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-1388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MV-CHIK - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCV-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NS4 for Chikungunya Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chikungunya Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Chikungunya - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tatbeclin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VLA-1553 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chikungunya Fever - Dormant Projects
Chikungunya Fever - Product Development Milestones
Featured News & Press Releases
Jan 09, 2017: Profectus BioSciences Bivalent Vaccine Protects Animals from Infection and Death After Exposure to Chikungunya or Zika Virus
Dec 19, 2016: UTMB researchers develop first chikungunya vaccine from virus that does not affect people
Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine
Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2
Mar 22, 2016: Inovio's DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases
Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus
Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1
Aug 14, 2014: Experimental chikungunya vaccine induces robust antibody response
Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful
Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate
Dec 20, 2011: NIAID Enrolls Participants In Chikungunya Vaccine Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Chikungunya Fever, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chikungunya Fever - Pipeline by Abivax SA, H1 2017
Chikungunya Fever - Pipeline by Arbovax Inc, H1 2017
Chikungunya Fever - Pipeline by Arno Therapeutics Inc, H1 2017
Chikungunya Fever - Pipeline by Bharat Biotech International Ltd, H1 2017
Chikungunya Fever - Pipeline by Ennaid Therapeutics LLC, H1 2017
Chikungunya Fever - Pipeline by Etubics Corp, H1 2017
Chikungunya Fever - Pipeline by Griffith University, H1 2017
Chikungunya Fever - Pipeline by Hawaii Biotech Inc, H1 2017
Chikungunya Fever - Pipeline by Indian Immunologicals Ltd, H1 2017
Chikungunya Fever - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Chikungunya Fever - Pipeline by Integral Molecular Inc, H1 2017
Chikungunya Fever - Pipeline by Integrated BioTherapeutics Inc, H1 2017
Chikungunya Fever - Pipeline by Merck & Co Inc, H1 2017
Chikungunya Fever - Pipeline by Mymetics Corp, H1 2017
Chikungunya Fever - Pipeline by Nanotherapeutics Inc, H1 2017
Chikungunya Fever - Pipeline by PaxVax Inc, H1 2017
Chikungunya Fever - Pipeline by Profectus BioSciences Inc, H1 2017
Chikungunya Fever - Pipeline by Shionogi & Co Ltd, H1 2017
Chikungunya Fever - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Chikungunya Fever - Pipeline by Themis Bioscience GmbH, H1 2017
Chikungunya Fever - Pipeline by Theravectys SA, H1 2017
Chikungunya Fever - Pipeline by Valneva SE, H1 2017
Chikungunya Fever - Pipeline by Vaxart Inc, H1 2017
Chikungunya Fever - Dormant Projects, H1 2017